SCHEMBL427562

SCHEMBL427562

CCN(C(=O)n1cnc(-c2ccccc2)c1)C1CCCCC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 2/20 0.56
CES2 O00748 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.50
SLC6A2 P23975 1/20 0.46
SLC6A4 P31645 1/20 0.46
ALDH1A1 P00352 1/20 0.43
S1PR1 P21453 1/20 0.42
S1PR3 Q99500 1/20 0.42
USP19 O94966 1/20 0.41
ATM Q13315 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
LMNA P02545 1/20 0.41
RAB9A P51151 2/20 0.40
NPC1 O15118 1/20 0.40
TRPV1 Q8NER1 2/20 0.40
TRPA1 O75762 1/20 0.40
MGLL Q99685 1/20 0.40
ADORA2A P29274 1/20 0.40
KCNK3 O14649 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL428153 0.90 FAAH (0.52) FAAHCES2L3MBTL1ALDH1A1MEN1
SCHEMBL425912 0.87 FAAH (0.49) FAAHCES2ALDH1A1MEN1KMT2A
SCHEMBL427646 0.86 FAAH (0.48) FAAHCES2S1PR1S1PR3RAB9A
SCHEMBL428158 0.86 FAAH (0.78) FAAHCES2L3MBTL1SLC6A2SLC6A4
SCHEMBL425897 0.85 FAAH (0.47) FAAHCES2L3MBTL1ALDH1A1MEN1
SCHEMBL425994 0.85 FAAH (0.47) FAAHCES2L3MBTL1ATMMEN1
SCHEMBL424383 0.85 FAAH (0.74) FAAHCES2L3MBTL1ALDH1A1S1PR1
SCHEMBL424654 0.83 TSHR (0.48) FAAHCES2S1PR1S1PR3MEN1
SCHEMBL427958 0.82 SMN1; SMN2 (0.52) FAAHCES2L3MBTL1ALDH1A1ATM
SCHEMBL12116968 0.81 DAGLA (0.54) L3MBTL1RAB9ANPC1TRPV1TRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
WO-2010074588-A2 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2010-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS FAAH, FAAH2, ASAH1 FAAH 1/4885CES2 62/4885L3MBTL1 4550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.